Testing new combination treatments for advanced esophageal cancer

Plain-English translation of NCT07554456 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing , a new cancer-fighting medication, combined with other drugs to treat advanced esophageal squamous cell carcinoma—a type of cancer in the food pipe that has spread or cannot be removed by surgery. Researchers want to see if this new medication combination works better and is safer than the standard chemotherapy that doctors typically use first. About 90 people will participate and be randomly assigned to receive one of three different treatment combinations.

Currently, patients with this type of advanced esophageal cancer have limited treatment options, and standard chemotherapy doesn't work well enough for everyone. This trial is exploring whether the new medication could be a more effective choice for these patients.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced esophageal squamous cell carcinoma that cannot be surgically removed or has come back after treatment
you have never received chemotherapy or immunotherapy for this cancer before (first-line treatment)
you are in good enough overall health to tolerate the study treatments, with an expected survival of at least 3 months
you have a measurable tumor that can be seen on imaging scans
you are able to provide a tissue sample from your tumor collected within the past 3 years

You likely don't qualify if…

you have received prior immunotherapy targeting PD-1, PD-L1, or PD-L2
you have a history of a different type of cancer diagnosed within the past 3 years
you have serious heart or lung disease, including a history of interstitial lung disease
you have uncontrolled high blood pressure, blood sugar, or blood clotting problems
you are currently taking high-dose steroids or immunomodulatory drugs

What participation looks like

You will be randomly assigned to one of three treatment groups. You will receive intravenous (IV) infusions of your assigned medication combination in treatment cycles lasting 3 weeks each. If the treatment is working and you're tolerating it well, you'll continue with additional cycles. Your doctors will monitor you closely for side effects and how well the treatment is working, and treatment will stop if your cancer worsens or if side effects become too difficult to manage.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Testing new combination treatments for advanced esophageal cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)